transmembrane protein 240Genealiases: C1orf70 · SCA21
Q-omics provides the consensus-scored TMEM240 profile across patient tissues and cancer cell-line models. TMEM240 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM240 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, TMEM240 RNA expression shows 16,675 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KICH, and TGCT as cancer lineages where TMEM240 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM240 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM240 survival associations across molecular data types. TMEM240 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM240 RNA expression–survival associations across cancer types. High TMEM240 expression shows unfavorable associations in ACC, MESO, KIRC, LUSC and COAD, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM240 RNA expression.
This table summarizes TMEM240 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM240. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM240 shows lower tumor expression in KICH, UCEC, BLCA and BRCA and higher tumor expression in LIHC and HNSC. The KICH box plot shows higher TMEM240 RNA expression in normal versus tumor tissue (log2 FC = −1.058, t-test p < 0.001).
This table shows molecular features associated with TMEM240 in patient tissues and cancer cell lines. In patient samples, TMEM240 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM240 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
